Tirzepatide vs Semaglutide: A Practical Comparison

Tirzepatide (sold as Mounjaro and Zepbound) and semaglutide (sold as Ozempic and Wegovy) are the two main entries in the modern GLP-1 medication class. They share a lot. They differ in one key way that turns out to matter quite a bit at maximum doses.

Here is the practical comparison beyond the brand names.

What They Share

Both are once weekly subcutaneous injections. Both work by mimicking the GLP-1 hormone, reducing appetite and slowing gastric emptying. Both improve blood sugar control and produce weight reduction. Both have similar side effect profiles dominated by gastrointestinal effects in the early weeks. Both require slow titration starting at a low dose.

For most patients on most days, the experience is similar.

The Key Difference

Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). GIP is a separate gut hormone with its own effects on insulin release, fat tissue, and possibly appetite regulation.

At maximum tolerated doses, this second pathway translates into stronger effects. Larger weight reduction. Larger HbA1c reduction. The size of the difference is real but not enormous. It matters more for people seeking maximum weight reduction than for people seeking modest reduction.

The Head To Head Data

The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in adults with obesity (without diabetes) over 72 weeks. Mean weight reduction was around 20 percent on tirzepatide and around 14 percent on semaglutide.

For diabetes, the SURPASS-2 trial compared the two at various doses in people with type 2 diabetes. Tirzepatide produced larger HbA1c reductions across all dose comparisons.

Both produced meaningful results. Both worked. Tirzepatide worked more.

Side Effects Compared

Broadly similar profiles. The same gastrointestinal effects in similar proportions in the early weeks. Most studies show no significant difference in side effect rates between the two at comparable dose stages.

Individual variation does exist. Some people tolerate one better than the other. Some find one suppresses appetite more strongly. There is no reliable way to predict in advance which will suit a particular person.

Frequency And Dosing

Both are weekly. Both titrate up over months. The dose numbers themselves are not comparable (different molecules at different potencies). What matters is the schedule and the side effect adaptation, both of which are similar in principle.

South African Context

At the time of writing, Mounjaro (tirzepatide) is the practical option for weight management in SA because it is the only SAHPRA approved option with the right indication and reasonable availability:

• Mounjaro: SAHPRA registered, approved for both type 2 diabetes (Dec 2024) and chronic weight management (Oct 2025). Distributed by Aspen.
• Ozempic (semaglutide): Registered for diabetes only. Not approved for weight management.
• Wegovy (semaglutide): Not yet registered with SAHPRA.

This is a regulatory reality, not a comparison of medications. Globally semaglutide remains a strong option for both indications.

Switching Between Them

Switching is occasionally done, usually because:

• The first medication is poorly tolerated
• Response is inadequate at maximum dose
• Supply issues with one but not the other
• Cost differences for the specific patient

Switching usually involves starting the new medication at a low dose and titrating up. There is no direct dose conversion because the molecules differ. The treating doctor handles the transition.

Cost Comparison

In SA, both Mounjaro and Ozempic sit in similar ranges per month at typical doses. Mounjaro tends to be slightly higher at higher doses but not far apart. Both are substantially more expensive than older diabetes or weight management medications.

Which Suits Whom

Tirzepatide leans favoured for

• People seeking maximum weight reduction
• People with very high HbA1c needing large reductions
• Weight management specifically in SA (regulatory status)

Semaglutide leans favoured for

• People who tolerated it well previously
• People with documented cardiovascular benefit data needs (more long term outcome data exists for semaglutide currently)
• People with restricted availability or formulary cover only for semaglutide

Real World Practical Note

The right medication is the one that works for you, is available, is affordable, and is tolerated. The 5 percent average weight reduction difference at maximum doses matters in the trial population but matters less if it means the difference between you being on a medication or not. A medication you can actually access and afford long term will outperform one with marginally better trial data that you cannot maintain.